Uncertainty in CRISPR world and the start of more M&A

What was the mood like at a big gene therapy conference last week? Why is Novo Nordisk’s CEO stepping down? And why has Adam been in such a good mood?

We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We chat about M&A deals picking up, leadership changes at Novo, and recent FDA advisory committee meetings for cancer drugs.